BioWorld Asia

Oct. 9, 2002

View Archived Issues

New Schizophrenia Gene Flags Up Opportunities For Fresh Therapies

Xerion Raises EUR12.3M To Develop Antibody, Cardiovascular Pipeline

X-SCID Treatment To Continue In UK Despite Halting In France

Baby Sister Conceived To Cure Brother's Inherited Anemia

Etiologics Spun Out To Focus On Mouse Genetics Capabilities

Peptech Granted TNF Antibody Patent; Centocor To Pay Royalties

Mtm, EMBLEM Collaborate In Bioinformatics, Cancer

Burrill & Co. Forms Alliance With PricewaterhouseCoopers Israel

Other News To Note

Genome Of Malaria-Carrying Mosquito Fully Sequenced

GLSV Launches EUR143M Fund, Seeks Strong Biotech Leaders

MUNICH, Germany - Global Life Science Ventures GmbH raised €143 million for a new fund that will invest in private biotechnology companies in Europe and the U.S. (Bioworld International Read More

French Gene Therapy Trial Halted After Adverse Event

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...